Triple
T2523475
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CBD |
E55577
|
entity |
| Predicate | approvedDrugForm |
P39643
|
FINISHED |
| Object |
Epidiolex
Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
|
E275978
|
NE FINISHED |
How this triple was built (5 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Epidiolex | Statement: [CBD, approvedDrugForm, Epidiolex]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Epidiolex Context triple: [CBD, approvedDrugForm, Epidiolex]
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
C.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Epidiolex Triple: [CBD, approvedDrugForm, Epidiolex]
Generated description
Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Epidiolex Target entity description: Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
C.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
- F. None of above. chosen
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: approvedDrugForm Context triple: [CBD, approvedDrugForm, Epidiolex]
-
A.
hasDosageForm
Indicates the specific physical form or presentation in which a drug or medicinal product is supplied or administered (e.g., tablet, injection, cream).
-
B.
FDAApprovalType
Indicates the specific regulatory pathway or category under which a product has been approved by the U.S. Food and Drug Administration.
-
C.
isExtendedReleaseFormulationOf
Indicates that one pharmaceutical formulation is an extended-release version of another, designed to release the active ingredient more slowly over time.
-
D.
isProdrugOf
Indicates that one substance is a precursor form that is metabolized in the body to produce the active form of another substance.
-
E.
isFirstDrugApprovedFor
Indicates that a drug is the earliest or original medication approved for treating a particular condition, disease, or indication.
- F. None of above. chosen
Provenance (7 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69ab49e4749c8190813311efd1630f1b |
completed | March 6, 2026, 9:40 p.m. |
| NER | Named-entity recognition | batch_69abd23a0a548190b44393e0f823f7a9 |
completed | March 7, 2026, 7:22 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69af2ba96a0c819091efd6d4ccf95ea5 |
completed | March 9, 2026, 8:20 p.m. |
| NEDg | Description generation | batch_69af508c28f48190afc4aa1bc3c9adf3 |
completed | March 9, 2026, 10:58 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69af5155f85081908dd4a1859d0f7907 |
completed | March 9, 2026, 11:01 p.m. |
| PD | Predicate disambiguation | batch_69abd0c144b0819092f32a13c1d127e5 |
completed | March 7, 2026, 7:16 a.m. |
| PDg | Predicate description generation | batch_69abd1487e0c8190b90dcf30586ad4cd |
completed | March 7, 2026, 7:18 a.m. |
Created at: March 6, 2026, 9:46 p.m.